James Parsons

Mr. James T. Parsons is a life sciences industry consultant and director. He previously served as the Chief Financial Officer of Trillium Therapeutics Inc. from 2011 to its acquisition by Pfizer in 2021 for $2.2 billion. Mr. Parsons has a broad background in the life sciences industry across therapeutics, diagnostics, and device companies. He has extensive experience in strategic planning, financing, contract negotiation, investor relations, risk management, corporate governance, and public company management. Mr. Parsons also serves on the Board of Directors of DiaMedica Therapeutics (Nasdaq: DMAC) and is chair of their audit committee and serves on the board of Oncolytics Biotech Inc (Nasdaq: ONCY). He has a master of accounting degree from the University of Waterloo and is a Chartered Professional Accountant, Chartered Accountant (CPA, CA).